Trial participation and vaccine desirability for Vi polysaccharide typhoid fever vaccine in Hue City, Viet Nam

被引:15
|
作者
Kaljee, Linda M. [1 ]
Pham, Van
Son, Nguyen Dinh
Hoa, Nguyen Thai
Thiem, Vu Dinh
Canh, Do Gia
Kim Thoa, Le Thi
Ali, Mohammad
Ochiai, Rion Leon
Danovaro-Holliday, M. Carolina
Acosta, Camilo J.
Stanton, Bonita
Clemens, John
机构
[1] Univ Maryland, Sch Med, Dept Pediat, Baltimore, MD 21201 USA
[2] Johns Hopkins Univ, Sch Publ Hlth, Baltimore, MD USA
[3] Prov Prevent Med Ctr, Hue City, Thua Thien, Vietnam
[4] Natl Inst Hyg & Epidemiol, Hanoi, Vietnam
[5] Ha Noi Med Univ, Hanoi, Vietnam
[6] Int Vaccine Inst, Seoul, South Korea
[7] Wayne State Univ, Sch Med, Carman & Ann Adams Dept Pediat, Detroit, MI USA
关键词
children/adolescents; enteric disease; vaccination; typhoid fever; Viet Nam;
D O I
10.1111/j.1365-3156.2006.01751.x
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
OBJECTIVES To identify demand for Vi typhoid fever vaccine for school-age children; obstacles and enabling factors for vaccine delivery; and socio-behavioural factors associated with trial participation and possible predictors of future vaccine acceptance, in Hue City, Viet Nam. METHODS Pre- and post-trial surveys of randomly selected households with children aged 6-17 years. Simple multinomial logistic analyses for ratios of relative risks (RRR) and significance on trial participation by demographics and variables related to typhoid fever, vaccination, and pre-trial experiences with information and consents. Multiple logistic regressions to assess differences in participation based on child's characteristics. RESULTS As many as 62.6% of households let all school age children participate, 10.2% let some participate, and 26.8% let none of their children participate in the trial. Factors associated with all children participating included past use of healthcare facilities (RRR, 0.45; 95% CI, 0.24-0.83), knowledge of vaccines (RRR, 0.17; 95% CI, 0.03-0.86), and perceived causes of typhoid fever (RRR, 0.90; 95% CI, 0.81-0.99). Factors associated with some children participating included utilization of healthcare facilities (RRR, 0.08; 95% CI, 0.01-0.66) and perceived severity of typhoid fever (RRR, 0.64; 95% CI 0.46-0.88). Participation was associated with satisfaction regarding pre-vaccination information and consent procedures. Children and adolescents were active decision-makers. Only 14 of 461 (2.2%) respondents would not use the Vi vaccine in the future for their child(ren). CONCLUSIONS Inter-related factors contribute to participation in a clinical vaccine trial, which may differ from desire to participate in a public health campaign. Educational campaigns need to be targeted to children and adolescents, and consideration for assent procedures for minors. Obtaining informed consent may affect trial participation within a social and political system unaccustomed to these procedures.
引用
收藏
页码:25 / 36
页数:12
相关论文
共 50 条
  • [41] A mass vaccination campaign targeting adults and children to prevent typhoid fever in Hechi; Expanding the use of Vi polysaccharide vaccine in Southeast China: A cluster-randomized trial
    Yang, J
    Acosta, CJ
    Si, GA
    Zeng, J
    Li, CY
    Liang, DB
    Ochiai, RL
    Page, AL
    Danovaro-Holliday, MC
    Zhang, J
    Zhou, BD
    Liao, HZ
    Wang, ML
    Tan, DM
    Tang, ZZ
    Gong, J
    Park, JK
    Ali, M
    Ivanoff, B
    Liang, GC
    Yang, HH
    Pang, T
    Xu, ZY
    Donner, A
    Galindo, CM
    Dong, BQ
    Clemens, JD
    BMC PUBLIC HEALTH, 2005, 5 (1)
  • [42] A Cluster-Randomized Effectiveness Trial of Vi Typhoid Vaccine in India REPLY
    Levine, Myron M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (22): : 2192 - 2193
  • [43] Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide
    Tacket, CO
    Pasetti, MF
    Sztein, MB
    Livio, S
    Levine, MM
    JOURNAL OF INFECTIOUS DISEASES, 2004, 190 (03): : 565 - 570
  • [44] Evaluation of a New Vi Polysaccharide Typhoid Vaccine in Children Aged 2-5 Years
    Leticia Cordero-Yap
    Religaya G. Rivera
    Alberto P. Dispo
    Julietta Mallabo
    BioDrugs, 2001, 15 : 27 - 27
  • [45] Cross-reactive immune response elicited by parenteral Vi polysaccharide typhoid vaccine against non-typhoid Salmonellae
    Pakkanen, Sari H.
    Kantele, Jussi M.
    Herzog, Christian
    Kantele, Anu
    VACCINE, 2014, 32 (05) : 544 - 551
  • [46] Re-evaluating herd protection by Vi typhoid vaccine in a cluster randomized trial
    Ali, Mohammad
    Sur, Dipika
    Kanungo, Suman
    Qadri, Firdausi
    Kim, Deok Ryun
    Islam, Taufiqul
    Im, Justin
    Ahmmed, Faisal
    Chon, Yun
    Khan, Ashraful Islam
    Zaman, K.
    Marks, Florian
    Dutta, Shanta
    Bhattacharya, Sujit K.
    Clemens, John D.
    INTERNATIONAL HEALTH, 2020, 12 (01): : 36 - 42
  • [47] Assessing the Impact of a Vi-polysaccharide Conjugate Vaccine in Preventing Typhoid Infection Among Bangladeshi Children: A Protocol for a Phase IIIb Trial
    Theiss-Nyland, Katherine
    Qadri, Firdausi
    Colin-Jones, Rachel
    Zaman, K.
    Khanam, Farhana
    Liu, Xinxue
    Voysey, Merryn
    Khan, Arifuzzaman
    Hasan, Nazmul
    Ashher, Fahim
    Farooq, Yama G.
    Pollard, Andrew J.
    Clemens, John D.
    CLINICAL INFECTIOUS DISEASES, 2019, 68 : S74 - S82
  • [48] Introducing Vi polysaccharide typhoid fever vaccine to primary school children in North Jakarta, Indonesia, via an existent school-based vaccination platform
    Agtini, M. D.
    Ochiai, R. L.
    Soeharno, R.
    Lee, H. J.
    Sundoro, J.
    Hadinegoro, S. R.
    Han, O. P.
    Tana, L.
    Halim, F. X. S.
    Ghani, L.
    Delima
    Lestari, W.
    Sintawati, F. X.
    Kusumawardani, N.
    Malik, R.
    Santoso, T. S.
    Nadjib, M.
    Soeroso, S.
    Wangsasaputra, F.
    Ali, M.
    Ivanoff, B.
    Galindo, C. M.
    Pang, T.
    Clemens, J. D.
    Suwandono, A.
    Acosta, C. J.
    PUBLIC HEALTH, 2006, 120 (11) : 1081 - 1087
  • [50] Reactogenicity and Immunogenicity of a Single Dose of Typhoid Vi Polysaccharide Vaccine in Children Aged between 4 and 14 Years
    Helena H. Pelser
    BioDrugs, 2001, 15 : 13 - 19